Ignite Creation Date:
2024-05-06 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05267106
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-27
First Post:
2022-02-15
Brief Title:
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
Sponsor:
Incyte Corporation
Organization:
Incyte Corporation
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-20
Start Date Type:
ACTUAL
Primary Completion Date:
2024-11-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-11-29
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-15
First Submit QC Date:
February 23 2022
Study First Post Date:
2022-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-26
Last Update Post Date:
2024-06-27
Last Update Post Date Type:
ACTUAL